VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The data, announced in a press release, demonstrate selective activity against cancer cells while sparing healthy cells in early testing, marking a step forward in the quest for more precise cancer therapies.
The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D). VERAXA will present its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the convention, highlighting its diversified oncology pipeline of antibody-based formats including ADCs, T-cell engagers (TCEs), and other antibody-based formats.
VERAXA’s proprietary BiTAC approach is designed to activate therapeutic effects only in targeted tumor cells, potentially reducing the off-target toxicity that often limits traditional cancer therapies. The newly released data showed that the BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results suggest a promising path toward more selective cancer treatments that could minimize damage to healthy tissues.
The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. This milestone provides VERAXA with access to public capital markets to advance its pipeline.
The implications of this announcement are significant for the oncology field. ADCs are a growing class of cancer drugs that combine antibodies with cytotoxic agents to deliver chemotherapy directly to cancer cells. However, many ADCs still cause side effects due to unintended release of the drug in healthy tissues. VERAXA’s BiTAC-ADC platform aims to address this limitation by requiring a second condition—tumor-specific activation—before the therapeutic effect occurs. If successful in further development, this technology could improve the therapeutic index of ADCs, potentially leading to more effective and safer treatments for patients.
For the industry, the technology represents a potential differentiator in the competitive ADC landscape. As more companies enter the ADC space, innovations that enhance selectivity could capture significant market interest. VERAXA’s engagement at BIO 2026, the industry’s largest partnering event, signals its intent to secure collaborations that could accelerate development and validation of its platforms.
Investors should note that the company’s forward-looking statements involve risks and uncertainties. As outlined in its SEC filings, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, actual results may differ materially from projections. The full terms of use and disclaimers are available on the InvestorBrandNetwork website (http://IBN.fm/Disclaimer). The latest news and updates relating to VRXA are available in the company’s newsroom (https://ibn.fm/VRXA).
